Levothyroxine Sodium Patent Expiration
Levothyroxine Sodium was first introduced by Jerome Stevens Pharmaceuticals Inc
Levothyroxine Sodium Patents
Given below is the list of patents protecting Levothyroxine Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tirosint-sol | US11241382 | Administration regimen of compositions of T4 thyroid hormone with high oral absorption | Sep 17, 2039 | Ibsa |
| Levolet | US10231931 | Thyroid hormone oral dosage forms and methods of using the same | Mar 23, 2038 | Genus Lifesciences |
| Levolet | US10406108 | Thyroid hormone oral dosage forms and methods of using the same | Mar 23, 2038 | Genus Lifesciences |
| Tirosint-sol | US10537538 | High-stability packaged solutions of T4 thyroid hormone | Feb 28, 2037 | Ibsa |
| Tirosint-sol | US11096913 | High-stability packaged solutions of T4 thyroid hormone | Feb 28, 2037 | Ibsa |
| Levothyroxine Sodium | US10398669 | Levothyroxine liquid formulations | Dec 01, 2036 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US11135190 | Levothyroxine liquid formulations | Dec 01, 2036 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US9782376 | Levothyroxine liquid formulations | Dec 01, 2036 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US11154498 | Stabilized liquid formulation of levothyroxine | Jul 20, 2036 | Hikma |
| Ermeza | US9345772 | Liquid levothyroxine formulations | Feb 27, 2035 | Mylan |
| Levothyroxine Sodium | US9006289 | Levothyroxine formulations | Oct 03, 2032 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US9168238 | Levothyroxine formulations | Aug 29, 2032 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US9168239 | Levothyroxine formulations | Aug 29, 2032 | Fresenius Kabi Usa |
| Thyquidity | US9050307 | Method for the preparation of a levothyroxine solution | Aug 06, 2031 | Stevens J |
| Tirosint | US7691411 | Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
Mar 14, 2024
(Expired) | Ibsa |
| Tirosint | US7723390 | Pharmaceutical formulations for thyroid hormones |
Mar 14, 2024
(Expired) | Ibsa |
| Tirosint | US7723390 | Pharmaceutical formulations for thyroid hormones |
Mar 14, 2024
(Expired) | Inst Biochimique |
| Levoxyl | US7101569 | Methods of administering levothyroxine pharmaceutical compositions |
Oct 02, 2023
(Expired) | King Pharms |
| Levoxyl | US6555581 | Levothyroxine compositions and methods |
Feb 15, 2022
(Expired) | King Pharms |
| Levoxyl | US7067148 | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
Feb 15, 2022
(Expired) | King Pharms |
| Levo-t | US6399101 | Stable thyroid hormone preparations and method of making same |
Mar 30, 2020
(Expired) | Cediprof Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Levothyroxine Sodium's patents.
Latest Legal Activities on Levothyroxine Sodium's Patents
Given below is the list recent legal activities going on the following patents of Levothyroxine Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jun, 2023 | US10537538 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Apr, 2023 | US9168238 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Apr, 2023 | US9168239 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Mar, 2023 | US10398669 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 Dec, 2022 | US9050307 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 01 Dec, 2022 | US9168238 |
| Email Notification Critical
| 01 Dec, 2022 | US9168239 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 01 Dec, 2022 | US9168239 |
| Email Notification Critical
| 01 Dec, 2022 | US9168238 |
| Correspondence Address Change Critical
| 21 Nov, 2022 | US9168238 |
Levothyroxine Sodium's Family Patents
